Non-Hodgkin Lymphoma
News
FDA lifts partial clinical hold on pidilizumab
The US Food and Drug Administration (FDA) has lifted the partial clinical hold on the investigational new drug (IND) application for pidilizumab (...
News
FDA approves ibrutinib as first-line CLL therapy
Photo courtesy of Janssen The US Food and Drug Administration (FDA) has approved the BTK inhibitor ibrutinib (Imbruvica) as a first-line...
News
FDA approves obinutuzumab for FL
The US Food and Drug Administration (FDA) has approved obinutuzumab (Gazyva) for certain patients with previously treated follicular lymphoma (FL...
News
AAs have lower rate of most blood cancers than NHWs
receiving treatment Photo by Rhoda Baer A new report suggests African Americans (AAs) have significantly lower rates of most hematologic...
News
Orphan designation recommended for BTK inhibitor
The European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) is recommending orphan designation for the second-generation BTK...
News
How an anticancer drug fights lymphoid malignancies
Photo by Cameron Wells, Walter and Eliza Hall Institute of Medical Research Research published in Cell Reports helps explain how the anticancer...
News
Teens’ weight, height linked to risk of NHL
A new analysis indicates that having a higher body weight and taller stature during adolescence may increase the risk of developing non-Hodgkin...
News
Drug shows promise for treating resistant AML, MCL
Preclinical research suggests the investigational anticancer drug ONC201 can be effective against mantle cell lymphoma (MCL) and acute myeloid...
Conference Coverage
Combo can produce durable remissions in PTCL
Photo by Larry Young SAN FRANCISCO—A combination treatment regimen can produce durable remissions in patients newly diagnosed with peripheral T-...
Conference Coverage
Chemo regimen can be ‘highly effective’ against ENKTL
Photo by Larry Young SAN FRANCISCO—A 3-agent chemotherapy regimen can be “highly effective” in patients with extranodal natural killer/T-cell...
Conference Coverage
Dual inhibitor could treat ATLL
Photo by Larry Young SAN FRANCISCO—Preclinical research suggests a compound that inhibits both EZH1 and EZH2 could be effective against adult T-...